WEGOVY FLEXTOUCH 0.5mg (Danish) Indications for Use
WEGOVY (semaglutide injection) is a prescription medication used for chronic weight management in adults who are either:
Obese (BMI ≥ 30 kg/m²)
Overweight (BMI ≥ 27 kg/m²) with weight-related health conditions such as hypertension, type 2 diabetes, or high cholesterol.
WEGOVY works by mimicking the action of GLP-1 (glucagon-like peptide-1), a hormone that helps regulate appetite and food intake. It makes patients feel fuller and reduces hunger. The drug should be used in conjunction with a reduced-calorie diet and increased physical activity.
Active ingredient: Semaglutide
Main function: Suppresses appetite and increases satiety to assist with weight loss
Administration: Weekly subcutaneous injection (under the skin)
WEGOVY FLEXTOUCH 0.5mg (Danish) Dosage Information
WEGOVY is available in a pre-filled pen and is administered once a week. The dosing schedule begins with a low dose that is gradually increased to the maintenance dose to reduce the likelihood of side effects.
Starting dose: 0.25 mg once a week
Dose escalation:
Weeks 1–4: 0.25 mg
Weeks 5–8: 0.5 mg
Weeks 9–12: 1 mg
Weeks 13–16: 1.7 mg
Maintenance dose (after Week 16): 2.4 mg weekly
Injection sites: Upper arms, thighs, or abdomen, with rotation of sites to avoid repeated injections in the same spot.
Patients should not exceed the recommended dose and must follow a diet and exercise plan set by their healthcare provider during treatment.
WEGOVY FLEXTOUCH 0.5mg (Danish) Side Effects and Precautions
Like any medication, WEGOVY may cause side effects. Most are mild and resolve over time as the body adjusts to the medication, but serious side effects may occur.
Very common side effects (affects more than 1 in 10 people):
Nausea or vomiting
Diarrhea
Constipation
Stomach pain
Fatigue
Headache
These are often temporary and may improve as treatment continues.
Common side effects (affects up to 1 in 10 people):
Indigestion and bloating
Burping or flatulence
Hair loss
Reflux or heartburn
Injection site reactions (pain, redness, or swelling)
Low blood sugar (hypoglycemia) in diabetic patients
Serious side effects (may require immediate medical attention):
Thyroid tumors or thyroid cancer: Signs include lumps in the neck, hoarseness, trouble swallowing, or shortness of breath. Patients with a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) should not use WEGOVY.
Pancreatitis: Symptoms include severe and persistent stomach pain that may radiate to the back.
Gallbladder disease: Sudden abdominal or back pain, often accompanied by nausea and vomiting.
Allergic reactions: Breathing difficulties, swelling of the face, lips, tongue, or throat, and a rapid heartbeat.
Patients should contact their healthcare provider immediately if they experience these symptoms.
Precautions:
WEGOVY is not recommended for individuals with type 1 diabetes or diabetic ketoacidosis.
Patients with a history of suicidal thoughts or depression should be closely monitored.
Pregnant or breastfeeding women should not use WEGOVY , as its effects on fetal development and breast milk are unknown.
Dehydration may occur due to vomiting or diarrhea. Patients should drink plenty of fluids.
WEGOVY FLEXTOUCH 0.5mg (Danish) Clinical Studies and Real-World Outcomes
Clinical trials for WEGOVY showed significant weight loss when combined with a calorie-reduced diet and physical activity. On average, patients experienced 10-15% body weight loss after sustained treatment.
Key findings:
Weight loss is typically 5-15% of total body weight, depending on adherence to the regimen.
Improvements in blood pressure, cholesterol levels, and blood sugar control were noted in participants with type 2 diabetes.
Patients reported increased satiety and reduced cravings.
WEGOVY FLEXTOUCH 0.5mg (Danish) Drug Interactions
WEGOVY may interact with other medications, particularly those that affect blood sugar levels or heart rate. The most common interactions involve diabetes medications.
Important drug interactions:
Insulin and sulfonylureas: Increased risk of hypoglycemia (low blood sugar). Adjustments in diabetic medications may be needed.
Hypertension and heart failure medications: Consult with a healthcare provider to manage dosing.
Medications for HIV, ADHD, or appetite suppression: Can increase the risk of side effects or reduce WEGOVY effectiveness.
Patients should inform their healthcare provider about all medications they are taking, including over-the-counter drugs, vitamins, and herbal supplements.
WEGOVY FLEXTOUCH 0.5mg (Danish) Instructions for Use
WEGOVY is administered via a single-use pre-filled pen. The injection is easy to self-administer, but patients must be trained by a healthcare professional before first use.
Steps to administer:
Prepare the pen: Ensure the solution is clear and colorless. Avoid use if it appears cloudy.
Choose an injection site: Rotate between the abdomen, thighs, or upper arms.
Inject: Press the pen against the skin and wait for the yellow bar to stop moving (indicating the injection is complete).
Dispose of the pen: Use a puncture-resistant sharps container to discard used pens.
WEGOVY® FLEXTOUCH 0.5mg (Danish) Contraindications and Warnings
WEGOVY® is contraindicated in:
Patients with a personal or family history of medullary thyroid carcinoma or MEN2.
Pregnant or breastfeeding women.
Individuals allergic to semaglutide or any other ingredients in the product.
Patients should undergo regular monitoring for thyroid function and pancreatitis while using WEGOVY.
